Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows.
The metabolic fate of erythropoietin (EPO) remains unknown. Urinary excretion does not appear to play a major role and liver catabolism has been shown to occur only after terminal sugars on the hormone have been removed. However, it has been proposed that EPO is eliminated by consumption in the bone marrow. In order to examine the extent of such consumption we measured the half-life of radioidinated recombinant EPO injected intravenously (IV) to rats with bone marrows suppressed by cyclophosphamide or hypertransfusion and marrows stimulated by phenylhydrazine or bleeding. The mean half-life or erythropoietin in normal rats was 179 +/- 16 min, with similar half-lives found in the other rats regardless of decreased or increased bone marrow activity. The results indicate that it is unlikely that erythroid activity determines EPO life span and catabolism.
Piroso
E
E
Cardeza Foundation for Hematologic Research Department of Internal Medicine, Philadelphia, PA 19107.
Erslev
A J
AJ
Flaharty
K K
KK
Caro
J
J
D000818:Animals; D001853:Bone Marrow / Q000002:abnormalities / Q000378:metabolism* / Q000473:pathology; D003520:Cyclophosphamide / Q000494:pharmacology; D004921:Erythropoietin / Q000008:administration & dosage / Q000378:metabolism*; D006207:Half-Life; D006470:Hemorrhage / Q000473:pathology; D006965:Hyperplasia / Q000378:metabolism / Q000473:pathology; D007275:Injections, Intravenous; D008297:Male; D010659:Phenylhydrazines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000378:metabolism
D010659:Phenylhydrazines; D011994:Recombinant Proteins; C030299:phenylhydrazine; D004921:Erythropoietin; D003520:Cyclophosphamide